Fergus Gleeson

Chromosomal instability shapes the tumor microenvironment of esophageal adenocarcinoma via a cGAS-chemokine-myeloid axis.

Beernaert B. et al, (2026), Sci Adv, 12

HIF-1–regulated TPM3 links hypoxia to motility and invasion beyond the hypoxic fraction in triple-negative breast cancer

Zhou C. et al, (2026), npj Breast Cancer

Fully automated volumetry of ventricular subregions on computed tomography using object detection and semantic segmentation.

Da Mutten R. et al, (2026), Neuroimage Rep, 6

Photon FLASH spares radiation-induced changes in cardiac function, remodelling and arrythmia in a preclinical model.

Ghita-Pettigrew M. et al, (2026), Radiother Oncol, 216

HLA Heterozygosity Influences Colorectal Cancer Risk and Survival Outcome.

Tsai Y-Y. et al, (2026), Gastroenterology, 170, 619 - 622

DESTINY-Gastric05 phase III trial of first-line trastuzumab deruxtecan, chemotherapy, and pembrolizumab in HER2-positive gastric or gastroesophageal junction cancer

Janjigian YY. et al, (2026), ESMO Gastrointestinal Oncology, 11

0594 Drug-testing in patient-derived renal cell carcinoma organoids reveals pathways of vulnerability and resistance

Steven M. et al, (2026), European Urology, 89, S1 - S2

The PRAGMATIC pathway - PRostate cancer diAGnosis and MAnagement Triage In Clinical care.

Sharma A. et al, (2026), BJU Int

Protocol of the RADIO-STAR trial: a phase 1 safety and dose finding study of hypofractionated radiotherapy to the stellate ganglia for the treatment of ventricular arrhythmia.

Bussmann BM. et al, (2026), BMJ Open, 16

Is liquid biopsy a cost-effective method to diagnose Burkitt Lymphoma in children and young adults? A health economic evaluation in Tanzania.

Jiang J. et al, (2026), BMC Med

Real-time intraoperative depth estimation in transsphenoidal surgery using deep learning: A feasibility study.

Zanier O. et al, (2026), J Clin Neurosci, 147

ssessing the effects of a 3D pathology tissue-processing workflow on downstream molecular analyses.

Baraznenok E. et al, (2026)

CMS subtypes correlate with complete response in trial of neoadjuvant Galunisertib plus chemoradiation in rectal cancer.

Rajamanickam V. et al, (2026), Transl Oncol, 66

Negative Selection Maintains Grossly Altered but Broadly Stable Karyotypes in Metastatic Colorectal Cancer.

Cross WCH. et al, (2026), Cancer Discov, 16, 218 - 234

Succinate receptor 1 restricts hematopoiesis and prevents acute myeloid leukemia progression.

Cuminetti V. et al, (2026), Nat Commun

Characterisation of bacteria-induced colitis and its modulation by probiotics in naked mole rats: a new mammalian model for acute inflammatory disease.

Hart DW. et al, (2026), J Pathol

Shortened High-dose Palliative Radiotherapy for Lung Cancer (SHiP-Rt): protocol for a single-arm, multicentre, phase II study.

Shrimali RK. et al, (2026), BMJ Open, 16

Bridging the gaps in fibroblast activation protein targeted radionuclide therapy: a translational perspective.

Wu C. et al, (2026), Eur J Nucl Med Mol Imaging

Survival outcomes of ERBB2-amplified metastatic colorectal cancer treated with first-line chemotherapy.

Matsubara Y. et al, (2026), Br J Cancer, 134, 463 - 468

Media coverage and PATHFINDER2: hype, simplification, and free advertising.

Turnbull C. et al, (2026), Lancet Oncol, 27, 144 - 145

Media coverage and PATHFINDER2: hype, simplification, and free advertising.

Turnbull C. et al, (2026), Lancet Oncol, 27, 144 - 145

Impact of high-dose vitamin D and calcium carbonate supplementation on bone density in adolescents living with HIV: a randomised, placebo-controlled trial.

Ferrand RA. et al, (2026), Lancet Child Adolesc Health, 10, 111 - 121

Impact and effective management of nausea/vomiting on patients treated with zolbetuximab + chemotherapy: insights from the phase III SPOTLIGHT and GLOW studies.

Shitara K. et al, (2026), ESMO Open, 11

ESMO Clinical Practice Guideline Express Update on the adoption of physical exercise in patients with localised colon cancer.

Pentheroudakis G. et al, (2026), ESMO Open, 11

Cumulative Absorbed Dose and Successive Cyclic Reduction in Absorbed Dose Predict Response to 177Lu-DOTATATE in Neuroendocrine Tumors.

Macsuka MJ. et al, (2026), J Nucl Med

Harness Behavioural Analysis for Unpacking the Bio-Interpretability of Pathology Foundation Models

Hu Y. et al, (2026)

Genomic risk model to implement precision prostate cancer screening in clinical care: the ProGRESS study.

Vassy JL. et al, (2026), Nat Cancer

Improved Safety of New MicroRNA-Regulated Oncolytic Coxsackievirus B3 Observed After Intravenous Administration in Colorectal-Tumor-Bearing Mice.

Elsner L. et al, (2026), Viruses, 18

Separate transcription and splicing gene networks are linked and coordinated by the pRb-E2F pathway.

Carr SM. et al, (2026), Nucleic Acids Res, 54

Circulating tumour cells as a window into lethality in prostate cancer.

Abusamra SM. et al, (2026), Nat Rev Urol

Fine-tuning BACH2 dosage balances stemness and effector function to enhance antitumor T cell therapy.

Conti AG. et al, (2026), Nat Immunol

TomoRay cranial: synthesis of cranial CT imaging from biplanar radiographs using a generative adversarial network.

Zanier O. et al, (2026), Eur Radiol

Mixed-model and transcriptome-wide association analyses identify transcription factors and genes associated with colorectal cancer susceptibility.

Chen Z. et al, (2026), Nat Commun, 17

call to standardize the definition of countries with a high-burden of sickle cell disease

Seabold A. et al, (2026), Journal of Sickle Cell Disease, 3

Promises under pressure: the modest predictive power of polygenic risk scores.

Horton R. et al, (2026), Eur J Hum Genet

High throughput mutational characterization of the GPCR ligand C5a using yeast display and deep sequencing.

Xu Y. et al, (2026), Structure, 34, 184 - 197.e4

Distinct regulatory elements of SLC6A14 expression contribute to modification of cystic fibrosis phenotypes.

Esmaeili M. et al, (2026), Hum Genet, 145

TMEM33 deletion potentiates anti-tumor CD8+ T cell immunity.

Jackson MT. et al, (2026), bioRxiv

Paclitaxel and rose bengal loaded microbubbles for the ultrasound targeted chemo-sonodynamic therapy of pancreatic cancer.

Wright J. et al, (2026), Eur J Pharm Biopharm, 218

cceptability of a virtual tour for anxiety alleviation in PET-CT - A pilot study.

Barnard MA. et al, (2026), Radiography (Lond), 32

Sigscores: summary scores for molecular signatures in R.

Barberis A. and Buffa FM., (2026), Bioinform Adv, 6

HER2 Protein Overexpression, mRNA Expression, and DNA Amplification Across Solid Tumors: Comparison of Next-Generation Sequencing-Based Assays With Immunohistochemistry.

Nagamine M. et al, (2026), JCO Precis Oncol, 10

Systemic complement protein levels as biomarkers of chemoradiotherapy response in anal squamous cell carcinoma.

Majorova D. et al, (2026), Radiother Oncol, 214

Correction: Preferences for multi-cancer tests (MCTs) in primary care: discrete choice experiments of general practitioners and the general public in England.

Buckell J. et al, (2026), Br J Cancer, 134, 175 - 176

Experimental Cancer Medicine Centre (ECMC) network proposal for a consensus gene panel for pan-cancer sequencing: a Delphi methodology.

Phillips R. et al, (2026), Br J Cancer, 134, 289 - 294

Lactation, tissue-resident immunity, and protection against breast cancer.

Little M. et al, (2026), Trends Immunol, 47, 3 - 5

Quantifying the flash effect and its dependence on average dose rate in vivo for 6 MeV electron and 6 MV photon beams.

Paillas S. et al, (2026), Clin Transl Radiat Oncol, 56

Paclitaxel and rose bengal loaded microbubbles for the ultrasound targeted chemo-sonodynamic therapy of pancreatic cancer.

Wright J. et al, (2026), Eur J Pharm Biopharm, 218

Progression-free survival as a surrogate for overall survival in gastro-esophageal cancer trials with immunotherapy: A meta-analysis.

Leone AG. et al, (2026), Eur J Cancer, 232

Current landscape, successes, and key challenges in cancer vaccine clinical trials across the UK.

Watson RA. et al, (2026), Lancet Oncol, 27, 19 - 22

Diagnostic accuracy of a ‘stage-gated’ approach for reporting prostate screening MRI: “Is less more?”

Thorley N. et al, (2026), European Radiology

Specialised or Generic? Tokenization Choices for Radiology Language Models

Warr H. et al, (2026), Lecture Notes in Computer Science, 16146 LNCS, 62 - 70

Integrating multi-omic datasets investigating stress response biology decodes prostate cancer dynamic disease progression and places IRE1 activity at the epicentre of acquired treatment resistance

Doultsinos D. et al, (2026), CANCER RESEARCH, 86

The Response

Bottini M. et al, (2026), NEUROSURGICAL FOCUS, 60

bstract PR013: Comprehensive spatial profiling of prostate cancer metastasis: Mapping clonal evolution, microenvironment dynamics, and early metastatic markers

He M. et al, (2026), CANCER RESEARCH, 86, PR13 - PR13

Trifluridine/tipiracil (FTD/TPI) in advanced gastric cancer-a retrospective cohort study providing real-world survival and safety data from the United Kingdom.

Salf J. et al, (2025), J Gastrointest Oncol, 16, 2584 - 2591

Impact of preoperative weight-loss interventions on outcomes after elective non-bariatric surgery: meta-analysis.

Wang D. et al, (2025), BJS Open, 10

Comparison between germline and somatic loss-of-function RNF43 mutations reveals different genotype-phenotype associations and provides insights into the genetic mechanisms of colorectal tumourigenesis.

Palles C. et al, (2025), Gut

High-Affinity Peptide-Drug Conjugate Ligands for the TRIM24 PHD and Bromodomain.

Platt MA. et al, (2025), Chemistry, 31

Benchmarking transformer-based models for medical record de-identification in a single center multi-specialty evaluation.

Kuo R. et al, (2025), iScience, 28

Hypercontractility and Oxidative Stress Drive Creatine Kinase Dysfunction in Hypertrophic Cardiomyopathy.

Xu A. et al, (2025), Circulation, 152, 1705 - 1727

Synthetic Imaging Methods: Ready for the Neurosurgical Operating Room?

Staartjes VE. et al, (2025), World Neurosurg, 206

Mathematical Modeling Quantifies "Just-Right" APC Inactivation for Colorectal Cancer Initiation.

Brunet Guasch M. et al, (2025), Cancer Res, 85, 5113 - 5127

Cost Effectiveness of Local Anaesthetic Transperineal Versus Transrectal Biopsy: Results from the TRANSLATE Study.

Little M. et al, (2025), Eur Urol Focus

Machine perfusion and single-cell spatial transcriptome mapping identifies novel immune escape mechanisms in colorectal cancer liver metastasis

Wan PK-T. et al, (2025)

Promising investigational agents for gastro-oesophageal junction adenocarcinoma.

Cammarota A. and Smyth E., (2025), Expert Opin Investig Drugs, 34, 953 - 956

ESMO guidance on the use of Large Language Models in Clinical Practice (ELCAP).

Wong EYT. et al, (2025), Ann Oncol, 36, 1447 - 1457

Preoperative Weight Loss in Patients With Excess Weight and Colorectal Cancer: The CARE Feasibility Randomized Clinical Trial.

Koutoukidis DA. et al, (2025), JAMA Netw Open, 8

First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors.

Cortés J. et al, (2025), Clin Cancer Res, 31, 4953 - 4963

Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients.

Sato T. et al, (2025), Clin Cancer Res, 31, 5027 - 5036

The human crisis in cancer: a Lancet Oncology Commission.

Rodin G. et al, (2025), Lancet Oncol, 26, e628 - e670

ctive Monitoring, Surgery, and Radiotherapy for Cribriform-Positive and Cribriform-Negative Prostate Cancer: A Secondary Analysis of the PROTECT Randomized Clinical Trial.

Sushentsev N. et al, (2025), JAMA Oncol, 11, 1512 - 1517

Long-term Outcomes Following Resection of Adenocarcinoma Arising from Intraductal Papillary Mucinous Neoplasm (A-IPMN) Versus Pancreatic Ductal Adenocarcinoma (PDAC): A Propensity-score Matched Analysis.

Lucocq J. et al, (2025), Ann Surg, 282, 1034 - 1044

Single-cell proteomics sheds light on neutrophil diversity in glioblastoma.

Skolariki A. and Parkes EE., (2025), Nat Rev Immunol, 25

Smartphone-based prediction of dopaminergic deficit in prodromal and manifest Parkinson's disease.

Gunter KM. et al, (2025), NPJ Digit Med, 8

Molecular phenotypes in early gallbladder and liver disease in the CFTR-/- sheep highlight aspects of cystic fibrosis-relevant hepatobiliary disease.

Meckler F. et al, (2025), Physiol Genomics, 57, 682 - 694

Clinical Impact of Next-Generation Sequencing-Guided Targeted Therapies in Advanced Cancer: A Systematic Review and Meta-Analysis.

Kazmi F. et al, (2025), Clin Oncol (R Coll Radiol), 48

2025 British Society for Haematology Guideline for the treatment of chronic lymphocytic leukaemia.

Walewska R. et al, (2025), Br J Haematol, 207, 2296 - 2313

DECOVID: A UK Two-Center Harmonized Database of Acute Care Electronic Health Records for COVID-19 Research

Aslett LJM. et al, (2025), Data, 10

Leveraging Large Language Models to Direct Automated PET/CT Tumour Segmentation in Retrospective Data: an Agentic Framework Method

Bonney LM. et al, (2025)

Enabling whole genome sequencing analysis from FFPE specimens in clinical oncology.

Domenico D. et al, (2025), Nat Commun, 16

Loss of IDH1 and IDH2 mutations during the evolution of metastatic chondrosarcoma.

Cross W. et al, (2025), Genome Biol, 26

Figure 1 from Attenuating Adaptive VEGF-A and IL8 Signaling Restores Durable Tumor Control in AR Antagonist–Treated Prostate Cancers

Maxwell PJ. et al, (2025)

Figure 5 from Attenuating Adaptive VEGF-A and IL8 Signaling Restores Durable Tumor Control in AR Antagonist–Treated Prostate Cancers

Maxwell PJ. et al, (2025)

Figure 4 from Attenuating Adaptive VEGF-A and IL8 Signaling Restores Durable Tumor Control in AR Antagonist–Treated Prostate Cancers

Maxwell PJ. et al, (2025)

Figure 2 from Attenuating Adaptive VEGF-A and IL8 Signaling Restores Durable Tumor Control in AR Antagonist–Treated Prostate Cancers

Maxwell PJ. et al, (2025)

Figure 3 from Attenuating Adaptive VEGF-A and IL8 Signaling Restores Durable Tumor Control in AR Antagonist–Treated Prostate Cancers

Maxwell PJ. et al, (2025)

Complex genotype-phenotype relationships shape the response to treatment of down syndrome childhood acute lymphoblastic leukaemia.

Lutz C. et al, (2025), Sci Rep, 15

Data from Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms

Larkin JR. et al, (2025)

Figure 2 from Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms

Larkin JR. et al, (2025)

Figure 3 from Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms

Larkin JR. et al, (2025)

Supplementary Table S1 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models

Rodriguez-Berriguete G. et al, (2025)

Supplementary Figure S3 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models

Rodriguez-Berriguete G. et al, (2025)

Supplementary Figure S4 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models

Rodriguez-Berriguete G. et al, (2025)

Figure 5 from Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms

Larkin JR. et al, (2025)

Figure 4 from VCAM-1–targeted MRI Improves Detection of the Tumor-brain Interface

Cheng VWT. et al, (2025)

Figure 5 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models

Rodriguez-Berriguete G. et al, (2025)

Supplementary Figure S6 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models

Rodriguez-Berriguete G. et al, (2025)

Figure 3 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models

Rodriguez-Berriguete G. et al, (2025)

Figure 4 from Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms

Larkin JR. et al, (2025)

Figure 3 from Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms

Larkin JR. et al, (2025)

Supplementary Table S1 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models

Rodriguez-Berriguete G. et al, (2025)

Figure 4 from VCAM-1–targeted MRI Improves Detection of the Tumor-brain Interface

Cheng VWT. et al, (2025)

Figure 2 from VCAM-1–targeted MRI Improves Detection of the Tumor-brain Interface

Cheng VWT. et al, (2025)

Figure 3 from VCAM-1–targeted MRI Improves Detection of the Tumor-brain Interface

Cheng VWT. et al, (2025)

Figure 3 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models

Rodriguez-Berriguete G. et al, (2025)

Inactivation of a protein hydroxylase complex impairs replication fork restart in cancer and neurodevelopmental disorders

Kennedy TJ. et al, (2025)

Data from Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms

Larkin JR. et al, (2025)

Data from VCAM-1–targeted MRI Improves Detection of the Tumor-brain Interface

Cheng VWT. et al, (2025)

Supplementary Figure S2 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models

Rodriguez-Berriguete G. et al, (2025)

Figure 5 from Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms

Larkin JR. et al, (2025)

Figure 4 from Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms

Larkin JR. et al, (2025)

Figure 5 from VCAM-1–targeted MRI Improves Detection of the Tumor-brain Interface

Cheng VWT. et al, (2025)

Supplementary Figure S1 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models

Rodriguez-Berriguete G. et al, (2025)

Supplementary Figure S4 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models

Rodriguez-Berriguete G. et al, (2025)

Supplementary Figures from GTP Cyclohydrolase Drives Breast Cancer Development and Promotes EMT in an Enzyme-Independent Manner

Wang Z. et al, (2025)

Supplementary Data from GTP Cyclohydrolase Drives Breast Cancer Development and Promotes EMT in an Enzyme-Independent Manner

Wang Z. et al, (2025)

Stable electron-irradiated [1-13C]alanine radicals for metabolic imaging with dynamic nuclear polarization.

Rooney CHE. et al, (2025), Sci Adv, 11

3D pathology-guided microdissection.

Hsieh H-C. et al, (2025)

RP1 Combined With Nivolumab in Advanced Anti-PD-1-Failed Melanoma (IGNYTE).

Wong MK. et al, (2025), J Clin Oncol, 43, 3589 - 3599

RP1 Combined With Nivolumab in Advanced Anti-PD-1-Failed Melanoma (IGNYTE).

Wong MK. et al, (2025), J Clin Oncol, 43, 3589 - 3599

Molecular basis for CSB stimulation of the SNM1A DNA repair nuclease.

Roddan R. et al, (2025)

Identification of conserved immune-related adverse event risk factors and clinical outcomes in a pan-immunotherapy data mart.

Lamparter DF. et al, (2025), J Immunother Cancer, 13

Neoadjuvant CTLA-4/PD-(L)1 Blockade Versus Surgery +/- Chemotherapy in Deficient Mismatch Repair/Microsatellite Instability-High Resectable Gastroesophageal Adenocarcinoma: Individual Patient Data Pooled Analysis.

Raimondi A. et al, (2025), J Clin Oncol, 43, 3457 - 3467

Research priorities for cancers of the oesophagus and stomach: recommendations from a UK and Ireland patient and healthcare professional partnership exercise.

Jones CM. et al, (2025), Gut, 74, 1949 - 1961

Personalising anal cancer radiotherapy dose (PLATO): protocol for a multicentre integrated platform trial.

Frood R. et al, (2025), BMJ Open, 15

Optimising antibiotic “review and revise” in acute/general medical inpatients: the Antibiotic Review Kit in Hospitals (ARK-Hospital) research programme including a stepped-wedge cluster-randomised trial

Llewelyn MJ. et al, (2025), NIHR Journals Library

The immunomodulatory role of human cytomegalovirus in cancer in the era of checkpoint immunotherapy.

Bremke J. et al, (2025), Philos Trans R Soc Lond B Biol Sci, 380

IGF-1 regulates cancer cell immune evasion in prostate cancer.

Nandakumar AM. et al, (2025), Sci Rep, 15

T cell engagers: expanding horizons in oncology and beyond.

Albayrak G. et al, (2025), Br J Cancer, 133, 1241 - 1249

Population screening for Helicobacter pylori to reduce gastric cancer - Authors' reply.

Sundar R. et al, (2025), Lancet, 406, 2060 - 2061

Novel ADAMTS13 Mutation in a Patient With Congenital TTP Diagnosed in Pregnancy.

Mawalla WF. et al, (2025), Am J Hematol, 100, 2093 - 2098

Replication-Competent, Tumor-Specific Immuno-Gene Vectors Allow for Exchange of Transgenes and Lead to Viral Persistence Following IV Administration.

Rosen LS. et al, (2025), J Immunother Precis Oncol, 8, 263 - 275

guide to reactive oxygen species in tumour hypoxia: measurement and therapeutic implications.

Hacker L. et al, (2025), Mol Oncol, 19, 3003 - 3022

multicenter phase II study of eribulin for BRAF V600E mutant metastatic colorectal cancer: the BRAVERY study (EPOC1701)

Masuishi T. et al, (2025), ESMO Open, 10

PD-1/PD-L1 inhibitors in advanced, unresectable esophageal squamous-cell carcinoma: A meta-analysis of their effects across patient subgroups

Beshr MS. et al, (2025), Critical Reviews in Oncology Hematology, 215

Large-scale meta-analysis and precision functional assays identify FANCM regions in which PTVs confer different risks for ER-negative and triple-negative breast cancer.

Billaud A. et al, (2025), Breast, 85

Laparoscopic versus open liver resection in patients aged at least 80 years: retrospective propensity score-matched cohort study.

Gómez-Gavara C. et al, (2025), BJS Open, 9

Reversible Enzymatic Switching of the Oxidation State of a EuIII/II Complex Controls Relaxivity.

Sarson ET. et al, (2025), J Am Chem Soc, 147, 38992 - 38997

Single-cell analysis uncovers preserved prostate cancer lineages and universally altered pathways in Matrigel-free patient-derived organoids.

Dolgos R. et al, (2025), Cell Rep, 44

Identification of a photoredox-active Pt(IV) complex that induces light-mediated cell death.

Marsh JW. et al, (2025), Chem Sci, 16, 19187 - 19191

Evidence of latent-lytic replication in EBV-positive Burkitt lymphoma from whole genome and transcriptome sequencing

Legason I. et al, (2025)

Ultrasound-Based Tomographic Imaging Reconstruction and Synthesis Methods: a Scoping Review.

de Wilde D. et al, (2025), J Imaging Inform Med

Subclonal immune evasion in non-small cell lung cancer.

Dijkstra KK. et al, (2025), Cancer Cell, 43, 1833 - 1849.e10

Impact of Human Epidermal Growth Factor Receptor 2 in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs: Exploratory Analysis of Eight Randomized Trials.

Germani MM. et al, (2025), J Clin Oncol, 43, 3184 - 3197

Indolequinone-Based Hypoxia-Activated Proteolysis Targeting Chimeras Selectively Degrade BRD4 in Hypoxic Cancer Cells.

Serafini M. et al, (2025), J Am Chem Soc, 147, 36352 - 36364

Degeneration and Impaired Resilience of Skull Bone and Hematopoietic Bone Marrow.

Yang Y. et al, (2025), bioRxiv

Pregnancy-associated venous thromboembolism in sub-Saharan Africa: a case-control study and descriptive analysis of clinical phenotypes.

Sango SP. et al, (2025), Res Pract Thromb Haemost, 9

phase 1b, multicentre, dose escalation, safety and pharmacokinetics study of tilvestamab (BGB149) in relapsed, platinum-resistant, high-grade serous ovarian cancer (PROC) patients.

Sooi K. et al, (2025), Br J Cancer, 133, 896 - 908

Detection of Genome-Wide IGF-1R Recruitment to Enhancer and Promoter Regions of Chromatin in Clinical Prostate Cancers.

Mills JV. et al, (2025), Cancer Med, 14

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with pancreatic cancer.

Tai D. et al, (2025), ESMO Open, 10

Genetic determinants of monocyte splicing are enriched for disease susceptibility loci.

Nassiri I. et al, (2025), Nat Commun, 16

Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia.

Munir T. et al, (2025), N Engl J Med, 393, 1177 - 1190

Silencing of SOD1 sensitises ATRX-deficient cells to camptothecin treatment through increased activity of the alternative lengthening of telomeres pathway.

Mattis N. et al, (2025), Hum Mol Genet, 34, 1638 - 1647

Learning Across the Divide: Personalised Federated Learning for Robust Clinical Modelling under Data-View Heterogeneity.

Molaei S. et al, (2025), IEEE J Biomed Health Inform, PP

Transposable elements as novel therapeutic targets for PARPi-induced synthetic lethality in PcG-mutated blood cancer.

Zeisig BB. et al, (2025), Blood, 146, 1314 - 1330

Circulating tumour DNA to augment PET-CT in determining clinical outcome after head and neck cancer treatment.

Bola S. et al, (2025), Eur J Cancer, 227

Galectin-3 induces neurodevelopmental apical-basal polarity and regulates gyrification.

Soares LC. et al, (2025), Sci Adv, 11

Tissue-specific iron levels modulate lipid peroxidation and the FLASH radiotherapy effect.

Vilaplana-Lopera N. et al, (2025), Cell Death Dis, 16

Precision Prevention Studies: A Targeted Approach to Cancer Prevention.

Blagden SP. et al, (2025), Cancer Prev Res (Phila), 18, 499 - 507

Pelvic stereotactic ablative body radiotherapy (SABR) reirradiation: UK SABR consortium guidance for use in routine clinical care.

Moreno-Olmedo E. et al, (2025), Tech Innov Patient Support Radiat Oncol, 35

Broadening our view of power in clinician-patient relationships in oncology.

Nimmon L. et al, (2025), Lancet Oncol, 26, 1140 - 1142

Cancer-associated fibroblasts are associated with neo-adjuvant treatment response in oesophageal adenocarcinoma.

Walker RC. et al, (2025), Br J Cancer, 133, 633 - 647

Research training, barriers, and career development needs of early-career investigators in oncology: an EORTC survey-based study.

Cammarota A. et al, (2025), ESMO Gastrointest Oncol, 9

ESMO podcast on upper gastrointestinal cancers-highlights in esophagogastric cancers from ASCO 2025.

Dekervel J. et al, (2025), ESMO Gastrointest Oncol, 9

Hypoxia-activated fluorescent probes as markers of oxygen levels in plant cells and tissues.

Perri M. et al, (2025), New Phytol, 247, 2998 - 3009

nalysis of IDH1 and IDH2 mutations as causes of the hypermethylator phenotype in colorectal cancer.

Ward JC. et al, (2025), J Pathol, 267, 40 - 55

FGFR2b protein overexpression: An emerging biomarker in gastric and gastroesophageal junction adenocarcinoma.

Smyth EC. et al, (2025), Cancer Treat Rev, 139

DNA methylation cooperates with genomic alterations during non-small cell lung cancer evolution.

Gimeno-Valiente F. et al, (2025), Nat Genet, 57, 2226 - 2237

Radiation dose escalation in locally advanced oesophageal cancer: a systematic review and hierarchical Bayesian meta-analysis.

Dai Y-H. et al, (2025), EClinicalMedicine, 87

Iatrogenic Subcapsular Haematoma Leads to 151% Growth of Future Liver Remnant.

Fu H. et al, (2025), Cardiovasc Intervent Radiol, 48, 1389 - 1391

Patient characteristics, serious disease diagnoses, and incidental findings in individuals with non-specific symptoms referred to the Suspected CANcer (SCAN) Pathway: a prospective cohort study in England

Friedemann Smith C. et al, (2025), The Lancet Primary Care, 1, 100019 - 100019

Not All Tumors Are Alike: Varying Efficacy of FLASH Across Tumor Types and Oxygenation Status in Spheroid Models.

Dela R. et al, (2025), Br J Radiol

Replication-associated mechanisms contribute to an increased CpG > TpG mutation burden in mismatch repair-deficient cancers.

Ward JC. et al, (2025), Genome Med, 17

Outcomes and Risk Factors for Complications of Dermis-Fat Graft as Primary Orbital Implant.

Schuh A. et al, (2025), Ophthalmic Plast Reconstr Surg

Tumor-specific CD8 T cell characterization in HR+ breast cancer reveals an impaired antitumoral response in patients with lymph node metastasis.

Pinho MP. et al, (2025), Cell Rep Med, 6

Platelets sequester extracellular DNA, capturing tumor-derived and free fetal DNA.

Murphy L. et al, (2025), Science, 389

HIBRID: histology-based risk-stratification with deep learning and ctDNA in colorectal cancer.

Loeffler CML. et al, (2025), Nat Commun, 16

Biomolecular tracking by FIRESCAPE reveals distinct modes of clearance, damage induction and cellular uptake for extracellular histone H3

Josephson B. et al, (2025)

GWAS meta-analysis identifies five susceptibility loci for endometrial cancer.

Ramachandran D. et al, (2025), EBioMedicine, 118

Landscape Analysis of CLDN18 Expression and Isoform Distribution in Solid Tumors: Insights From MONSTAR-SCREEN-2 Study.

Hashimoto T. et al, (2025), Cancer Sci, 116, 2218 - 2231

Investigating the therapeutic potential of FLASH radiotherapy - a treatment planning study.

Hörberger F. et al, (2025), Radiother Oncol, 209

Clinical Significance of Extrachromosomal DNA in FGFR2-Amplified Gastric Cancer: Therapeutic Implications From Clinical Experience.

Aoki Y. et al, (2025), JCO Precis Oncol, 9

Prognostic Indicators of Preoperative Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel Efficacy in Locally Advanced Gastroesophageal and Gastric Cancer: Integrating Biomarker Analysis and Clinicopathological Factors.

Jubashi A. et al, (2025), JCO Precis Oncol, 9

CFTR Gene Regulation in Human Pancreatic Duct, Bile Duct and Sweat Gland Epithelial Cells.

Umrigar A. et al, (2025), J Cell Mol Med, 29

Nanotechnology for immuno-oncology.

Grippin AJ. et al, (2025), Nat Cancer, 6, 1311 - 1325

Transcription-coupled repair of crosslinking DNA damage.

Roddan R. et al, (2025), DNA Repair (Amst), 152

Interactions between cancer-associated fibroblasts and the extracellular matrix in oesophageal cancer.

Vadibeler S. et al, (2025), Matrix Biol, 139, 49 - 60

Generation of synthetic tomographic images from biplanar X-ray: a narrative review of history, methods, and the state of the art.

Alakmeh A. et al, (2025), J Neurosurg Sci, 69, 350 - 361

GWAS meta-analysis identifies five susceptibility loci for endometrial cancer.

Ramachandran D. et al, (2025), EBioMedicine, 118

Charting New Paths in Cancer Research: Insights from the Frontiers in Cancer Science Conference 2024.

Le Minh G. et al, (2025), Cancer Res, 85, 2784 - 2787

Preferences for multi-cancer tests (MCTs) in primary care: discrete choice experiments of general practitioners and the general public in England.

Buckell J. et al, (2025), Br J Cancer, 133, 394 - 403

myloid-β disrupts APP-regulated protein aggregation and dissociation from recycling endosomal membranes.

Singh PJ. et al, (2025), EMBO J, 44, 4443 - 4472

systems-based approach to uterine fibroids identifies differential splicing associated with abnormal uterine bleeding.

Wang C-Y. et al, (2025), Commun Med (Lond), 5

Defining the genetic determinants of CD8+ T cell receptor repertoire in the context of immune checkpoint blockade.

Ng ES. et al, (2025), Sci Adv, 11

UPR-induced intracellular C5aR1 promotes adaptation to the hypoxic tumour microenvironment.

Suwa T. et al, (2025), Cell Death Dis, 16

Ex vivo model of functioning human lymph node reveals role for innate lymphocytes and stroma in response to vaccine adjuvant.

Fergusson JR. et al, (2025), Cell Rep, 44

Radiobiological characterisation of a 28 MeV proton beam delivered by the MC-40 cyclotron.

Fabbrizi MR. et al, (2025), Cell Death Discov, 11

Size matters: Micro- versus nanobubbles in ultrasound imaging and therapy.

Sheth M. et al, (2025), Sci Adv, 11

Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer.

Janjigian YY. et al, (2025), N Engl J Med, 393, 217 - 230

Clinical Validation of Liquid Biopsy for Faster Molecular Diagnosis of EBV-Positive Burkitt Lymphoma

Chamba C. et al, (2025)

Multiple highly methylated CpG sites as potential epigenetic markers for the diagnosis of prostate cancer.

Roperch J-P. et al, (2025), Clin Epigenetics, 17

The dual ubiquitin binding mode of SPRTN secures rapid spatiotemporal proteolysis of DNA-protein crosslinks.

Song W. et al, (2025), Nucleic Acids Res, 53

DriverOmicsNet: an integrated graph convolutional network for multi-omics exploration of cancer driver genes.

Dai Y-H. et al, (2025), Brief Bioinform, 26

Prognostic significance of circulating tumor DNA alterations in advanced renal cell carcinoma from SCRUM-Japan MONSTAR-SCREEN: a nationwide genomic profiling project.

Kato T. et al, (2025), Br J Cancer, 133, 111 - 120

Deep learning-based time-of-flight (ToF) enhancement of non-ToF PET scans for different radiotracers.

Mehranian A. et al, (2025), Eur J Nucl Med Mol Imaging, 52, 2968 - 2978

Spatial metabolomics informs the use of clinical imaging for improved detection of cribriform prostate cancer.

Sushentsev N. et al, (2025), Proc Natl Acad Sci U S A, 122

Recommendations for reporting preclinical radiobiological studies in targeted radionuclide therapy.

Mendes F. et al, (2025), Eur J Nucl Med Mol Imaging, 52, 3066 - 3070

The importance of standardization and challenges of dosimetry in conventional preclinical radiation biology research.

Hill MA. et al, (2025), Br J Radiol, 98, 993 - 1004

Generation of synthetic CT-like imaging of the spine from biplanar radiographs: comparison of different deep learning architectures.

Bottini M. et al, (2025), Neurosurg Focus, 59

CMV serostatus is associated with improved survival and delayed toxicity onset following anti-PD-1 checkpoint blockade.

Milotay G. et al, (2025), Nat Med, 31, 2350 - 2364

Recent Innovations to Foster Personalized Adaptive Radiation Therapy.

Harms J. et al, (2025), Int J Radiat Oncol Biol Phys, 122, 528 - 531

FLASH-induced DNA damage reduction measured in vitro correlates with effective oxygen depletion determined in silico: further support for oxygen depletion contributing to FLASH's reduced damage burden in vitro.

Rothwell B. et al, (2025), Br J Radiol, 98, 1032 - 1037

Megavoltage photon FLASH for preclinical experiments.

Taylor ERJF. et al, (2025), Med Phys, 52

Diagnosing Burkitt Lymphoma in Sub-Saharan Africa by Sequencing of Circulating Tumor DNA: A Comparative Microcosting Study.

Morrell L. et al, (2025), Value Health Reg Issues, 48

First in vitro and in vivo experiments with ultra high-dose rate oxygen ion radiotherapy.

Karle C. et al, (2025), Phys Imaging Radiat Oncol, 35

Deep learning image enhancement algorithms in PET/CT imaging: a phantom and sarcoma patient radiomic evaluation.

Bonney LM. et al, (2025), Eur J Nucl Med Mol Imaging, 52, 3266 - 3277

dvances in platinum-based cancer therapy: overcoming platinum resistance through rational combinatorial strategies.

Yusoh NA. et al, (2025), Med Oncol, 42

Tissue-Specific Iron Levels Modulate Lipid Peroxidation and the FLASH Radiotherapy Effect.

Vilaplana-Lopera N. et al, (2025)

Cellular imbalance in proximal and distal lung of CFTR-/- sheep in utero and at birth.

Leir S-H. et al, (2025), Mol Med, 31

Gastric cancer.

Sundar R. et al, (2025), Lancet, 405, 2087 - 2102

Impact of Long-Term Chemotherapy on Outcomes in Pancreatic Ductal Adenocarcinoma: A Real-World UK Multi-Centre Study.

Mahmood U. et al, (2025), Cancers (Basel), 17

Epithelial GREMLIN1 disrupts intestinal epithelial-mesenchymal crosstalk to induce a wnt-dependent ectopic stem cell niche through stromal remodelling.

Mulholland EJ. et al, (2025), Nat Commun, 16

Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with BRAFV600-Mutant Metastatic Melanoma.

Dummer R. et al, (2025), Clin Cancer Res, 31, 2097 - 2107

Correction: Highlight selection of radiochemistry and radiopharmacy developments by editorial board.

Spreckelmeyer S. et al, (2025), EJNMMI Radiopharm Chem, 10

Size Matters: Micro v. Nanobubbles in Ultrasound Imaging and Therapy Dataset

SHETH M. et al, (2025)

SRSF2 overexpression induces transcription-/replication-dependent DNA double-strand breaks and interferes with DNA repair pathways to promote lung tumor progression.

Khalife M. et al, (2025), NAR Cancer, 7

Chromothripsis-associated chromosome 21 amplification orchestrates transformation to blast-phase MPN through targetable overexpression of DYRK1A.

Brierley CK. et al, (2025), Nat Genet, 57, 1478 - 1492

Safe prescribing in cancer patients during the COVID-19 pandemic and outcomes following restart of cancer care following SARS-CoV-2 infection: The COV-SPOT initiative.

Appanna N. et al, (2025), Int J Cancer, 156, 2087 - 2093

The impact of model assumptions in interpreting cell kinetic studies.

Yan AWC. et al, (2025), PLoS Comput Biol, 21

CINs of the cytoplasm: dissecting dsRNA signaling in chromosomal instability.

Skolariki A. et al, (2025), Mol Oncol, 19, 1561 - 1564

Ectopic, intra-thyroid parathyroid adenoma better visualized by deep learning enhanced choline PET/CT.

Bradley KM. et al, (2025), QJM, 118, 466 - 467

Pan-Asia adapted ESMO Clinical Practice Guideline for the management of patients with newly diagnosed and relapsed epithelial ovarian cancer.

Nag S. et al, (2025), ESMO Open, 10

Novel Primary Cell Line Model of Localized Prostate Cancer and Radioresistance-A Role for Nicotinamide N-Methyltransferase.

Wright JA. et al, (2025), Cells, 14

Early mucosal responses following a randomised controlled human inhaled infection with attenuated Mycobacterium bovis BCG.

Marshall JL. et al, (2025), Nat Commun, 16

Binuclear Lanthanide Complexes as Magnetic Resonance and Optical Imaging Probes for Redox Sensing.

Simms CH. et al, (2025), Chemistry, 31

Screening for prostate cancer.

Kotecha P. et al, (2025), BMJ, 389

Rituximab for children with EBV-positive Burkitt lymphoma in East Africa.

Mawalla WF. et al, (2025), Blood Adv, 9, 2393 - 2401

Chromosomal instability shapes the tumor microenvironment of esophageal adenocarcinoma via a cGAS-chemokine-myeloid axis.

Beernaert B. et al, (2025)

GENESIS: Generating scRNA-Seq data from Multiome Gene Expression

Riva SG. et al, (2025)

Benchmarking transformer-based models for medical record deidentification: A single centre, multi-specialty evaluation

Kuo R. et al, (2025)

Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study.

Sawada K. et al, (2025), Cancer Res Commun, 5, 857 - 870

Gut microbiome associated with PARP inhibitor efficacy in patients with ovarian cancer.

Okazawa-Sakai M. et al, (2025), J Gynecol Oncol, 36

Neoadjuvant Treatment of Rectal Cancer: A Repeat UK-wide Survey After Implementation of National Intensity Modulated Radiotherapy Guidance.

Macnair A. et al, (2025), Clin Oncol (R Coll Radiol), 41

novel fast strategy to calculate equieffective doses under different dose rate conditions.

Macsuka MJ. et al, (2025), Med Phys, 52, 3416 - 3427

Simultaneous versus delayed resection of synchronous colorectal liver metastases: A systematic review and meta-analysis.

Lakha AS. et al, (2025), Eur J Surg Oncol, 51

Local anaesthetic transperineal biopsy versus transrectal prostate biopsy in prostate cancer detection (TRANSLATE): a multicentre, randomised, controlled trial.

Bryant RJ. et al, (2025), Lancet Oncol, 26, 583 - 595

High-performance automated abstract screening with large language model ensembles.

Sanghera R. et al, (2025), J Am Med Inform Assoc, 32, 893 - 904

Performance analysis of an artificial intelligence algorithm for detection and localisation of tracheal tube position by chest radiography.

Novak A. et al, (2025), Br J Anaesth, 134, 1554 - 1557

survey of dosimetry quality assurance practice at UK small animal radiation research platform (SARRP) facilities.

Biglin ER. et al, (2025), Biomed Phys Eng Express, 11

The role of MLH1, MSH2 and MSH6 in the development of colorectal cancer in Uganda.

Wismayer R. et al, (2025), BMC Cancer, 25

TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumors.

Plummer R. et al, (2025), Cell Rep Med, 6

Induction of macrophage efferocytosis in pancreatic cancer via PI3Kγ inhibition and radiotherapy promotes tumour control.

Russell SN. et al, (2025), Gut, 74, 825 - 839

LnDOTA Releasing Probes for Luminescence and Magnetic Resonance Imaging.

Foster CA. et al, (2025), Inorg Chem, 64, 6640 - 6647

Genetic variation at 11q23.1 confers colorectal cancer risk by dysregulation of colonic tuft cell transcriptional activator POU2AF2.

Rajasekaran V. et al, (2025), Gut, 74, 787 - 803

Supplementary Figure S1 from Combined Oxygen-Enhanced MRI and Perfusion Imaging Detect Hypoxia Modification from Banoxantrone and Atovaquone and Track Their Differential Mechanisms of Action

O’Connor JPB. et al, (2025)

Supplementary Figure S3 from Combined Oxygen-Enhanced MRI and Perfusion Imaging Detect Hypoxia Modification from Banoxantrone and Atovaquone and Track Their Differential Mechanisms of Action

O’Connor JPB. et al, (2025)

Supplementary Figure S5 from Combined Oxygen-Enhanced MRI and Perfusion Imaging Detect Hypoxia Modification from Banoxantrone and Atovaquone and Track Their Differential Mechanisms of Action

O’Connor JPB. et al, (2025)

Supplementary Figure S6 from Combined Oxygen-Enhanced MRI and Perfusion Imaging Detect Hypoxia Modification from Banoxantrone and Atovaquone and Track Their Differential Mechanisms of Action

O’Connor JPB. et al, (2025)

Supplementary Figure S4 from Combined Oxygen-Enhanced MRI and Perfusion Imaging Detect Hypoxia Modification from Banoxantrone and Atovaquone and Track Their Differential Mechanisms of Action

O’Connor JPB. et al, (2025)

Supplementary Figure S1 from Combined Oxygen-Enhanced MRI and Perfusion Imaging Detect Hypoxia Modification from Banoxantrone and Atovaquone and Track Their Differential Mechanisms of Action

O’Connor JPB. et al, (2025)

Data from Combined Oxygen-Enhanced MRI and Perfusion Imaging Detect Hypoxia Modification from Banoxantrone and Atovaquone and Track Their Differential Mechanisms of Action

O’Connor JPB. et al, (2025)

Supplementary Figure S3 from Combined Oxygen-Enhanced MRI and Perfusion Imaging Detect Hypoxia Modification from Banoxantrone and Atovaquone and Track Their Differential Mechanisms of Action

O’Connor JPB. et al, (2025)

Meta-Analysis and Meta-Regression of the Efficacy, Toxicity, and Quality of Life Outcomes Following Prostate-Specific Membrane Antigen Radioligand Therapy Utilising Lutetium-177 and Actinium-225 in Metastatic Prostate Cancer.

Dai Y-H. et al, (2025), Eur Urol, 87, 398 - 408

Coevolution of Atypical BRAF and KRAS Mutations in Colorectal Tumorigenesis.

Woolley CE. et al, (2025), Mol Cancer Res, 23, 300 - 312

Self-interactive learning: Fusion and evolution of multi-scale histomorphology features for molecular traits prediction in computational pathology.

Hu Y. et al, (2025), Med Image Anal, 101

Preclinical Evaluation of 177Lu-rhPSMA-10.1, a Radiopharmaceutical for Prostate Cancer: Biodistribution and Therapeutic Efficacy.

Foxton C. et al, (2025), J Nucl Med, 66, 599 - 604

Theranostics for Neuroblastoma: Making Molecular Radiotherapy Work Better.

Gawne PJ. et al, (2025), J Nucl Med, 66, 490 - 496

spirin prevents metastasis by limiting platelet TXA2 suppression of T cell immunity.

Yang J. et al, (2025), Nature, 640, 1052 - 1061

Clinicomolecular Profile and Efficacy of Human Epidermal Growth Factor Receptor 2 (HER2)-Targeted Therapy for HER2-Amplified Advanced Biliary Tract Cancer.

Inoue K. et al, (2025), JCO Precis Oncol, 9

Strategies for generating synthetic computed tomography-like imaging from radiographs: A scoping review.

De Wilde D. et al, (2025), Med Image Anal, 101

Lymph node yield as a surrogate marker for tumour biology and prognosis in colon cancer.

Bundred J. et al, (2025), Br J Cancer, 132, 643 - 651

Benefits of Combining Circulating Tumor DNA With Tissue and Longitudinal Circulating Tumor DNA Genotyping in Advanced Solid Tumors: SCRUM-Japan MONSTAR-SCREEN-1 Study.

Fujisawa T. et al, (2025), JCO Precis Oncol, 9

Japan society of clinical oncology position paper on appropriate clinical use of molecular residual disease (MRD) testing.

Kobayashi S. et al, (2025), Int J Clin Oncol, 30, 605 - 654

Supplementary Table 2 from Coevolution of Atypical BRAF and KRAS Mutations in Colorectal Tumorigenesis

Woolley CE. et al, (2025)

Table 2 from Coevolution of Atypical BRAF and KRAS Mutations in Colorectal Tumorigenesis

Woolley CE. et al, (2025)

Supplementary Figure 1 from Coevolution of Atypical BRAF and KRAS Mutations in Colorectal Tumorigenesis

Woolley CE. et al, (2025)

Supplementary Table 3 from Coevolution of Atypical BRAF and KRAS Mutations in Colorectal Tumorigenesis

Woolley CE. et al, (2025)

Supplementary Figure 4 from Coevolution of Atypical BRAF and KRAS Mutations in Colorectal Tumorigenesis

Woolley CE. et al, (2025)

Supplementary Text 1 from Coevolution of Atypical BRAF and KRAS Mutations in Colorectal Tumorigenesis

Woolley CE. et al, (2025)

Supplementary Table 6 from Coevolution of Atypical BRAF and KRAS Mutations in Colorectal Tumorigenesis

Woolley CE. et al, (2025)

Supplementary Table 2 from Coevolution of Atypical BRAF and KRAS Mutations in Colorectal Tumorigenesis

Woolley CE. et al, (2025)

Supplementary Figure 3 from Coevolution of Atypical BRAF and KRAS Mutations in Colorectal Tumorigenesis

Woolley CE. et al, (2025)

Supplementary Table 5 from Coevolution of Atypical BRAF and KRAS Mutations in Colorectal Tumorigenesis

Woolley CE. et al, (2025)

Figure 4 from Coevolution of Atypical BRAF and KRAS Mutations in Colorectal Tumorigenesis

Woolley CE. et al, (2025)

Table 2 from Coevolution of Atypical BRAF and KRAS Mutations in Colorectal Tumorigenesis

Woolley CE. et al, (2025)

Table 1 from Coevolution of Atypical BRAF and KRAS Mutations in Colorectal Tumorigenesis

Woolley CE. et al, (2025)

Supplementary Text 1 from Coevolution of Atypical BRAF and KRAS Mutations in Colorectal Tumorigenesis

Woolley CE. et al, (2025)

Supplementary Data 1 from Coevolution of Atypical BRAF and KRAS Mutations in Colorectal Tumorigenesis

Woolley CE. et al, (2025)

Supplementary Table 4 from Coevolution of Atypical BRAF and KRAS Mutations in Colorectal Tumorigenesis

Woolley CE. et al, (2025)

Supplementary Table 9 from Coevolution of Atypical BRAF and KRAS Mutations in Colorectal Tumorigenesis

Woolley CE. et al, (2025)

Supplementary Table 3 from Coevolution of Atypical BRAF and KRAS Mutations in Colorectal Tumorigenesis

Woolley CE. et al, (2025)

Supplementary Figure 2 from Coevolution of Atypical BRAF and KRAS Mutations in Colorectal Tumorigenesis

Woolley CE. et al, (2025)

Figure 5 from Coevolution of Atypical BRAF and KRAS Mutations in Colorectal Tumorigenesis

Woolley CE. et al, (2025)

Data from Coevolution of Atypical BRAF and KRAS Mutations in Colorectal Tumorigenesis

Woolley CE. et al, (2025)

Supplementary Table 7 from Coevolution of Atypical BRAF and KRAS Mutations in Colorectal Tumorigenesis

Woolley CE. et al, (2025)

Neoadjuvant immunotherapy for esophageal cancer: have we been in the era?

Zhu H. and Smyth EC., (2025), Annals of Esophagus, 8

Highlight selection of radiochemistry and radiopharmacy developments by editorial board.

Spreckelmeyer S. et al, (2025), EJNMMI Radiopharm Chem, 10

Next-generation sequencing for guiding matched targeted therapies in people with relapsed or metastatic cancer.

Kazmi F. et al, (2025), Cochrane Database Syst Rev, 3

Circulating Tumor DNA Assessment to Predict Risk of Recurrence after Surgery in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma: A Prospective Observational Study.

Takei S. et al, (2025), Ann Surg

IRE1 activity regulates tumour and microenvironment cell lineage states while stratifying localised and metastatic prostate cancer

Doultsinos D. et al, (2025)

IPEM code of practice for proton therapy dosimetry based on the NPL primary standard proton calorimeter calibration service.

Green S. et al, (2025), Phys Med Biol, 70

Optimal timing for initiating first-line palliative systemic therapy in asymptomatic metastatic esophagogastric cancer: Insights from a European Delphi study.

Kamp D. et al, (2025), Eur J Cancer, 218

Estimating Long-Term Survivorship Rates Among Patients With Resected Stage III/IV Melanoma: Analyses From CheckMate 238 and European Organization for Research and Treatment of Cancer 18071 Trials.

Weber JS. et al, (2025), J Clin Oncol, 43, 929 - 937

Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib.

Coombes RC. et al, (2025), Nat Commun, 16

GeneFEAST: the pivotal, gene-centric step in functional enrichment analysis interpretation.

Taylor A. et al, (2025), Bioinformatics, 41

Regional patterns of early-onset colorectal cancer from the GEOCODE (Global Early-Onset COlorectal Cancer DatabasE)-European consortium: retrospective cohort study.

Daca-Alvarez M. et al, (2025), BJS Open, 9

Mathematical Modeling Predicts Optimal Immune Checkpoint Inhibitor and Radiotherapy Combinations and Timing of Administration.

Sakai SA. et al, (2025), Cancer Immunol Res, 13, 353 - 364

Supplementary Figure S1 from Mathematical Modeling Predicts Optimal Immune Checkpoint Inhibitor and Radiotherapy Combinations and Timing of Administration

Sakai SA. et al, (2025)

Supplementary Figure S7 from Mathematical Modeling Predicts Optimal Immune Checkpoint Inhibitor and Radiotherapy Combinations and Timing of Administration

Sakai SA. et al, (2025)

Supplementary Figure S2 from Mathematical Modeling Predicts Optimal Immune Checkpoint Inhibitor and Radiotherapy Combinations and Timing of Administration

Sakai SA. et al, (2025)

Table S1 from Mathematical Modeling Predicts Optimal Immune Checkpoint Inhibitor and Radiotherapy Combinations and Timing of Administration

Sakai SA. et al, (2025)

Data from Mathematical Modeling Predicts Optimal Immune Checkpoint Inhibitor and Radiotherapy Combinations and Timing of Administration

Sakai SA. et al, (2025)

Supplementary Figure S9 from Mathematical Modeling Predicts Optimal Immune Checkpoint Inhibitor and Radiotherapy Combinations and Timing of Administration

Sakai SA. et al, (2025)

Supplementary Figure S3 from Mathematical Modeling Predicts Optimal Immune Checkpoint Inhibitor and Radiotherapy Combinations and Timing of Administration

Sakai SA. et al, (2025)

Supplementary Figure S5 from Mathematical Modeling Predicts Optimal Immune Checkpoint Inhibitor and Radiotherapy Combinations and Timing of Administration

Sakai SA. et al, (2025)

Supplementary Figure S6 from Mathematical Modeling Predicts Optimal Immune Checkpoint Inhibitor and Radiotherapy Combinations and Timing of Administration

Sakai SA. et al, (2025)

Supplementary Figure S4 from Mathematical Modeling Predicts Optimal Immune Checkpoint Inhibitor and Radiotherapy Combinations and Timing of Administration

Sakai SA. et al, (2025)

Supplementary Figure S8 from Mathematical Modeling Predicts Optimal Immune Checkpoint Inhibitor and Radiotherapy Combinations and Timing of Administration

Sakai SA. et al, (2025)

How do I treat dMMR/MSI gastro-oesophageal adenocarcinoma in 2025? A position paper from the EORTC-GITCG gastro-esophageal task force.

de la Fouchardière C. et al, (2025), Cancer Treat Rev, 134

Sustained cancer-relevant alternative RNA splicing events driven by PRMT5 in high-risk neuroblastoma.

Bate-Eya LT. et al, (2025), Mol Oncol, 19, 741 - 763

How do I treat dMMR/MSI gastro-oesophageal adenocarcinoma in 2025? A position paper from the EORTC-GITCG gastro-esophageal task force.

de la Fouchardière C. et al, (2025), Cancer Treat Rev, 134

Systematic Approach to Prioritise Diagnostically Useful Findings for Inclusion in Electronic Health Records as Discrete Data to Improve Clinical Artificial Intelligence Tools and Genomic Research.

Guillod P. et al, (2025), Clin Oncol (R Coll Radiol), 39

Dedicated centres and multinational platforms to improve patient care and address early-onset cancers.

Ben-Aharon I. et al, (2025), Nat Rev Cancer, 25, 145 - 146

Targeting HER2 in Gastroesophageal Cancer: A New Appetite for an Old Plight.

Cammarota A. et al, (2025), Drugs, 85, 361 - 383

Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial.

Okines AFC. et al, (2025), Nat Med, 31, 909 - 916

ImmuneLENS characterizes systemic immune dysregulation in aging and cancer.

Bentham R. et al, (2025), Nat Genet, 57, 694 - 705

Quality of English- and Spanish-language online content about prostate cancer genetics: Insights into potential contributors to prostate cancer disparities.

Abusamra SM. et al, (2025), BJUI Compass, 6

Estimation of Maximum Obtainable RBE ‘Turnover-Points’ (LETU) for Accelerated Ions Based on a Nuclear Charge Radius Hypothesis to Obtain Iso-Effective LET and RBE Values

Jones B., (2025), Biophysica, 5

Fully automated grading of pituitary adenoma

Da Mutten R. et al, (2025), NeuroImage: Reports, 5

commentary on: “Effect of Preoperative Autologous Blood Storage in Major Hepatectomy for Perihilar Malignancy: A Randomized Controlled Trial”

Lakha AS. and Gordon-Weeks A., (2025), AME Surgical Journal, 5

Data to support manuscript: 'CMV serostatus is associated with improved survival and delayed toxicity onset following immune checkpoint blockade'

FAIRFAX B., (2025)

Breaking barriers: we need a multidisciplinary approach to tackle cancer drug resistance.

Ingham J. et al, (2025), BJC Rep, 3

Recurrent ERBB2 alterations are associated with esophageal adenocarcinoma brain metastases.

Lawson NM. et al, (2025)

Radiomics for Treatment Planning in Liver Cancers.

Mian A. et al, (2025), JAMA Surg

Rare disease gene association discovery in the 100,000 Genomes Project.

Cipriani V. et al, (2025), Nature

Hypoxia-activated fluorescent probes as markers of oxygen levels in plant cells and tissues

Perri M. et al, (2025)

ccelerating the Future of Oncology Drug Development: The Role of Consortia in the Delivery of Precision Oncology Early Phase Clinical Trials.

Liu J. et al, (2025), J Clin Oncol, 43, 735 - 747

Lessons learned from a candidate gene study investigating aromatase inhibitor treatment outcome in breast cancer.

Hoppe R. et al, (2025), NPJ Breast Cancer, 11

Time to return of bowel function following perioperative probiotics in colorectal cancer surgery (PICCS-1): study protocol for a randomized controlled trial.

Chan DKH. et al, (2025), Trials, 26

TR-hippo drives force signaling to nuclear F-actin and links mechanotransduction to neurological disorders.

Chatzifrangkeskou M. et al, (2025), Sci Adv, 11

Defining hypoxia in cancer: A landmark evaluation of hypoxia gene expression signatures.

Di Giovannantonio M. et al, (2025), Cell Genom, 5

Protocol for a randomised phase 3 trial evaluating the role of Finasteride in Active Surveillance for men with low and intermediate-risk prostate cancer: the FINESSE Study.

Cumberbatch M. et al, (2025), BMJ Open, 15

constitutive interferon-high immunophenotype defines response to immunotherapy in colorectal cancer.

Acha-Sagredo A. et al, (2025), Cancer Cell, 43, 292 - 307.e7

Elevated reactive oxygen species can drive the alternative lengthening of telomeres pathway in ATRX-null cancers.

Goncalves T. et al, (2025), Nucleic Acids Res, 53

Elevated reactive oxygen species can drive the alternative lengthening of telomeres pathway in ATRX-null cancers.

Goncalves T. et al, (2025), Nucleic Acids Res, 53

Distinct immune cell infiltration patterns in pancreatic ductal adenocarcinoma (PDAC) exhibit divergent immune cell selection and immunosuppressive mechanisms.

Sivakumar S. et al, (2025), Nat Commun, 16

Phantom-based investigation of block sequential regularised expectation maximisation (BSREM) reconstruction for zirconium-89 PET-CT for varied count levels.

Bonney LM. et al, (2025), EJNMMI Phys, 12

n ultra-conserved poison exon in the Tra2b gene encoding a splicing activator is essential for male fertility and meiotic cell division.

Dalgliesh C. et al, (2025), EMBO J, 44, 877 - 902

Expanding therapeutic options targeting claudin-18.2.

Herbert K. and Smyth EC., (2025), Lancet Oncol, 26, 153 - 155

Classification of variants of reduced penetrance in high-penetrance cancer susceptibility genes: Framework for genetics clinicians and clinical scientists by CanVIG-UK (Cancer Variant Interpretation Group-UK).

Garrett A. et al, (2025), Genet Med, 27

Tumour purity assessment with deep learning in colorectal cancer and impact on molecular analysis.

Schoenpflug LA. et al, (2025), J Pathol, 265, 184 - 197

Oxygen consumption measurements at ultra-high dose rate over a wide LET range.

Karle C. et al, (2025), Med Phys, 52, 1323 - 1334

djuvant immunotherapy in patients with resected gastric and oesophagogastric junction cancer following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1): European Organisation of Research and Treatment of Cancer (EORTC) 1707 VESTIGE study.

Lordick F. et al, (2025), Ann Oncol, 36, 197 - 207

Hypoxia promotes tumor immune evasion by suppressing MHC-I expression and antigen presentation.

Estephan H. et al, (2025), EMBO J, 44, 903 - 922

Conserved patterns of transcriptional dysregulation, heterogeneity, and cell states in clear cell kidney cancer.

Lombardi O. et al, (2025), Cell Rep, 44

Isostere 18 F-protein post-translational editing enables dynamic tracking of neurodegeneration biomarkers

Yang N. et al, (2025)

Specificity of a polygenic score for aggressive prostate cancer.

Dornisch AM. et al, (2025)

Translation of PET radiotracers for cancer imaging: recommendations from the National Cancer Imaging Translational Accelerator (NCITA) consensus meeting.

McAteer MA. et al, (2025), BMC Med, 23

Tumor-Naïve ctDNA Assay Detects Minimal Residual Disease in Resected Stage II or III Colorectal Cancer and Predicts Recurrence: Subset Analysis from the GALAXY Study in CIRCULATE-Japan.

Nakamura Y. et al, (2025), Clin Cancer Res, 31, 328 - 338

Supplementary Table S3 from A Tumor-Naïve ctDNA Assay Detects Minimal Residual Disease in Resected Stage II or III Colorectal Cancer and Predicts Recurrence: Subset Analysis from the GALAXY Study in CIRCULATE-Japan

Nakamura Y. et al, (2025)

Supplementary Table S1 from A Tumor-Naïve ctDNA Assay Detects Minimal Residual Disease in Resected Stage II or III Colorectal Cancer and Predicts Recurrence: Subset Analysis from the GALAXY Study in CIRCULATE-Japan

Nakamura Y. et al, (2025)

Supplementary Table S4 from A Tumor-Naïve ctDNA Assay Detects Minimal Residual Disease in Resected Stage II or III Colorectal Cancer and Predicts Recurrence: Subset Analysis from the GALAXY Study in CIRCULATE-Japan

Nakamura Y. et al, (2025)

Supplementary Table S2 from A Tumor-Naïve ctDNA Assay Detects Minimal Residual Disease in Resected Stage II or III Colorectal Cancer and Predicts Recurrence: Subset Analysis from the GALAXY Study in CIRCULATE-Japan

Nakamura Y. et al, (2025)

Supplementary Figure S3 from A Tumor-Naïve ctDNA Assay Detects Minimal Residual Disease in Resected Stage II or III Colorectal Cancer and Predicts Recurrence: Subset Analysis from the GALAXY Study in CIRCULATE-Japan

Nakamura Y. et al, (2025)

Data from A Tumor-Naïve ctDNA Assay Detects Minimal Residual Disease in Resected Stage II or III Colorectal Cancer and Predicts Recurrence: Subset Analysis from the GALAXY Study in CIRCULATE-Japan

Nakamura Y. et al, (2025)

Supplementary Figure S1 from A Tumor-Naïve ctDNA Assay Detects Minimal Residual Disease in Resected Stage II or III Colorectal Cancer and Predicts Recurrence: Subset Analysis from the GALAXY Study in CIRCULATE-Japan

Nakamura Y. et al, (2025)

Supplementary Figure S2 from A Tumor-Naïve ctDNA Assay Detects Minimal Residual Disease in Resected Stage II or III Colorectal Cancer and Predicts Recurrence: Subset Analysis from the GALAXY Study in CIRCULATE-Japan

Nakamura Y. et al, (2025)

Prospective and genetic analyses implicate lower immunosurveillance in the aetiology of prostate cancer

Smith-Byrne K. et al, (2025)

Multimodal cell-free DNA whole-genome TAPS is sensitive and reveals specific cancer signals.

Vavoulis DV. et al, (2025), Nat Commun, 16

DNA-damage orchestrates self-renewal and differentiation via reciprocal p53 family and Hippo/Wnt/TGF-β pathway activation in embryonic stem cells.

Ye Y. et al, (2025), Cell Mol Life Sci, 82

Targeting c-MET for Endoscopic Detection of Dysplastic Lesions within Barrett's Esophagus Using EMI-137 Fluorescence Imaging.

Huang Y-J. et al, (2025), Clin Cancer Res, 31, 98 - 109

Figure 1 from Targeting c-MET for Endoscopic Detection of Dysplastic Lesions within Barrett’s Esophagus Using EMI-137 Fluorescence Imaging

Huang Y-J. et al, (2025)

Supplementary Information S1 from Targeting c-MET for Endoscopic Detection of Dysplastic Lesions within Barrett’s Esophagus Using EMI-137 Fluorescence Imaging

Huang Y-J. et al, (2025)

Supplementary Video S1 from Targeting c-MET for Endoscopic Detection of Dysplastic Lesions within Barrett’s Esophagus Using EMI-137 Fluorescence Imaging

Huang Y-J. et al, (2025)

Figure 4 from Targeting c-MET for Endoscopic Detection of Dysplastic Lesions within Barrett’s Esophagus Using EMI-137 Fluorescence Imaging

Huang Y-J. et al, (2025)

Figure 3 from Targeting c-MET for Endoscopic Detection of Dysplastic Lesions within Barrett’s Esophagus Using EMI-137 Fluorescence Imaging

Huang Y-J. et al, (2025)

Figure 2 from Targeting c-MET for Endoscopic Detection of Dysplastic Lesions within Barrett’s Esophagus Using EMI-137 Fluorescence Imaging

Huang Y-J. et al, (2025)

Supplementary Table S1 from Targeting c-MET for Endoscopic Detection of Dysplastic Lesions within Barrett’s Esophagus Using EMI-137 Fluorescence Imaging

Huang Y-J. et al, (2025)

Supplementary Figure S4 from Targeting c-MET for Endoscopic Detection of Dysplastic Lesions within Barrett’s Esophagus Using EMI-137 Fluorescence Imaging

Huang Y-J. et al, (2025)

Figure 4 from Targeting c-MET for Endoscopic Detection of Dysplastic Lesions within Barrett’s Esophagus Using EMI-137 Fluorescence Imaging

Huang Y-J. et al, (2025)

Supplementary Figure S1 from Targeting c-MET for Endoscopic Detection of Dysplastic Lesions within Barrett’s Esophagus Using EMI-137 Fluorescence Imaging

Huang Y-J. et al, (2025)

Figure 1 from Targeting c-MET for Endoscopic Detection of Dysplastic Lesions within Barrett’s Esophagus Using EMI-137 Fluorescence Imaging

Huang Y-J. et al, (2025)

Data from Targeting c-MET for Endoscopic Detection of Dysplastic Lesions within Barrett’s Esophagus Using EMI-137 Fluorescence Imaging

Huang Y-J. et al, (2025)

Supplementary Table S1 from Targeting c-MET for Endoscopic Detection of Dysplastic Lesions within Barrett’s Esophagus Using EMI-137 Fluorescence Imaging

Huang Y-J. et al, (2025)

Supplementary Figure S4 from Targeting c-MET for Endoscopic Detection of Dysplastic Lesions within Barrett’s Esophagus Using EMI-137 Fluorescence Imaging

Huang Y-J. et al, (2025)

Supplementary Figure S5 from Targeting c-MET for Endoscopic Detection of Dysplastic Lesions within Barrett’s Esophagus Using EMI-137 Fluorescence Imaging

Huang Y-J. et al, (2025)

Supplementary Figure S2 from Targeting c-MET for Endoscopic Detection of Dysplastic Lesions within Barrett’s Esophagus Using EMI-137 Fluorescence Imaging

Huang Y-J. et al, (2025)

Table 1 from Targeting c-MET for Endoscopic Detection of Dysplastic Lesions within Barrett’s Esophagus Using EMI-137 Fluorescence Imaging

Huang Y-J. et al, (2025)

Tislelizumab efficacy and safety compared to other anti-PD-1s: a network meta-analysis of first-line therapies for unresectable, locally advanced or metastatic esophageal squamous cell carcinoma.

Ajani JA. et al, (2025), Front Immunol, 16

The Impact of Body Mass Index (BMI) on Clinical Outcomes for Patients Receiving Systemic Anti-Cancer Therapies for Advanced Clear Cell Renal Carcinoma.

Greene J. et al, (2025), Cancer Control, 32

Detection of Germline Variants in Patients With Localized and Metastatic Prostate Cancer Through Guideline-Based Testing.

Abusamra SM. et al, (2025), Urol Pract, 12, 63 - 72

Cancer vaccine trial evaluations: immunobridging and potential immunological endpoints.

Hussain A. et al, (2025), Immunother Adv, 5

Utilization of Fetal Hemoglobin Parameters in Predicting Clinical Severity of Sickle Cell Disease: Retrospective Study From a Tanzanian Cohort.

Haji HM. et al, (2025), J Blood Med, 16, 321 - 330

Low survival in younger adults with Acute Myeloid Leukemia (AML) in Tanzania linked to high disease burden and socioeconomic factors.

Munroe M. et al, (2025), PLoS One, 20

Tracking cortical entrainment to stages of optic-flow processing.

Wingfield C. et al, (2025), Vision Res, 226

nalysis of sagittal plane cine magnetic resonance imaging for measurement of pancreatic tumor residual motion during breath hold and evaluation of gating margins used in radiotherapy treatment.

Phipps A. et al, (2025), J Appl Clin Med Phys, 26

Clinical Implications of Basic Research: Exploring the Transformative Potential of Spatial 'Omics in Uro-oncology.

Figiel S. et al, (2025), Eur Urol, 87, 8 - 14

MetE: a promising protective antigen for tuberculosis vaccine development.

Almujri SS. et al, (2025), Front Immunol, 16

Clonal phylogenies inferred from bulk, single cell, and spatial transcriptomic analysis of epithelial cancers.

Erickson A. et al, (2025), PLoS One, 20

Cookies on this website

Contact information

Research groups

Websites

Fergus Gleeson

Research Summary

Biography

Key publications